Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
VaxGen |
---|---|
Information provided by: | VaxGen |
ClinicalTrials.gov Identifier: | NCT00103467 |
The purpose of this phase 1 study is to evaluate the safety and immunogenicity of rPA102 vaccine, using anthrax vaccine adsorbed (AVA) as a comparator.
Condition | Intervention | Phase |
---|---|---|
Prevention of Anthrax Infection |
Biological: rPA102 Vaccine |
Phase I |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase 1 Trial to Evaluate the Safety and Immunogenicity of an Anthrax Recombinant Protective Antigen Vaccine |
Ages Eligible for Study: | 18 Years to 40 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, Georgia | |
Emory University School of Medicine | |
Atlanta, Georgia, United States, 30322 | |
United States, Maryland | |
Dept. of International Health - Johns Hopkins University Bloomberg School of Public Health | |
Baltimore, Maryland, United States, 21205 | |
United States, Missouri | |
St. Louis University - SoLutions/SLUtest | |
St. Louis, Missouri, United States, 63104 | |
United States, Texas | |
Baylor College of Medicine | |
Houston, Texas, United States, 77030 |
Study ID Numbers: | VAX005 |
Study First Received: | February 8, 2005 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00103467 |
Health Authority: | United States: Food and Drug Administration |
Bacterial Infections Gram-Positive Bacterial Infections Anthrax |
Bacillaceae Infections Infection |